SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.840
+0.050 (1.32%)
Mar 9, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Cash & Equivalents | 10.5 | 8.9 | 56.57 | 15.05 | 33.21 | Upgrade
|
| Short-Term Investments | 86.09 | 11.86 | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 96.59 | 20.76 | 56.57 | 15.05 | 33.21 | Upgrade
|
| Cash Growth | 365.27% | -63.30% | 275.93% | -54.69% | 163.33% | Upgrade
|
| Accounts Receivable | - | - | - | 5.56 | 8.01 | Upgrade
|
| Other Receivables | 0.95 | 0.05 | - | - | - | Upgrade
|
| Receivables | 0.95 | 0.05 | - | 5.56 | 8.01 | Upgrade
|
| Prepaid Expenses | 3.51 | 2.98 | 2.34 | 1.49 | 2.64 | Upgrade
|
| Restricted Cash | - | - | - | - | 6.34 | Upgrade
|
| Total Current Assets | 101.05 | 23.79 | 58.91 | 22.1 | 50.19 | Upgrade
|
| Property, Plant & Equipment | 19.4 | 19.92 | 24.68 | 28.34 | 30.95 | Upgrade
|
| Long-Term Investments | 46.89 | - | - | - | - | Upgrade
|
| Long-Term Deferred Charges | 0.15 | 0.26 | - | - | - | Upgrade
|
| Other Long-Term Assets | 5.31 | 0.22 | 0.35 | 0.47 | - | Upgrade
|
| Total Assets | 172.81 | 44.2 | 83.94 | 50.9 | 81.14 | Upgrade
|
| Accounts Payable | 3.15 | 1.69 | 0.95 | 3.68 | 4.46 | Upgrade
|
| Accrued Expenses | 6.58 | 5.47 | 6.69 | 9.83 | 11.91 | Upgrade
|
| Current Portion of Long-Term Debt | - | 0.28 | 1.05 | 0.77 | 1.8 | Upgrade
|
| Current Portion of Leases | 0.95 | 0.54 | 0.8 | 0.62 | 1.3 | Upgrade
|
| Current Unearned Revenue | - | - | 1.32 | - | 0.1 | Upgrade
|
| Other Current Liabilities | - | - | - | 0.09 | 6.89 | Upgrade
|
| Total Current Liabilities | 10.68 | 7.98 | 10.81 | 14.99 | 26.46 | Upgrade
|
| Long-Term Debt | - | - | - | 0.54 | - | Upgrade
|
| Long-Term Leases | 5 | 3.86 | 4.05 | 3.99 | 5.42 | Upgrade
|
| Other Long-Term Liabilities | 5.64 | 6.39 | 11.77 | 0.32 | 10.72 | Upgrade
|
| Total Liabilities | 21.32 | 18.23 | 26.64 | 19.85 | 42.59 | Upgrade
|
| Common Stock | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 267.72 | 155.79 | 152.86 | 84.45 | 67.67 | Upgrade
|
| Retained Earnings | -110.9 | -124.17 | -90.06 | -47.87 | -29.13 | Upgrade
|
| Treasury Stock | -5.52 | -5.52 | -5.52 | -5.52 | - | Upgrade
|
| Comprehensive Income & Other | 0.19 | -0.14 | 0.03 | - | - | Upgrade
|
| Total Common Equity | 151.49 | 25.97 | 57.3 | 31.06 | 38.55 | Upgrade
|
| Shareholders' Equity | 151.49 | 25.97 | 57.3 | 31.06 | 38.55 | Upgrade
|
| Total Liabilities & Equity | 172.81 | 44.2 | 83.94 | 50.9 | 81.14 | Upgrade
|
| Total Debt | 5.95 | 4.67 | 5.91 | 5.93 | 8.52 | Upgrade
|
| Net Cash (Debt) | 90.64 | 16.09 | 50.66 | 9.12 | 24.69 | Upgrade
|
| Net Cash Growth | 463.28% | -68.23% | 455.59% | -63.07% | 450.61% | Upgrade
|
| Net Cash Per Share | 1.48 | 1.74 | 9.17 | 2.09 | 9.03 | Upgrade
|
| Filing Date Shares Outstanding | 50.95 | 9.29 | 9.23 | 5.04 | 4.3 | Upgrade
|
| Total Common Shares Outstanding | 47.61 | 9.29 | 9.23 | 5.04 | 4.35 | Upgrade
|
| Working Capital | 90.37 | 15.81 | 48.09 | 7.1 | 23.74 | Upgrade
|
| Book Value Per Share | 3.18 | 2.80 | 6.21 | 6.16 | 8.86 | Upgrade
|
| Tangible Book Value | 151.49 | 25.97 | 57.3 | 31.06 | 38.55 | Upgrade
|
| Tangible Book Value Per Share | 3.18 | 2.80 | 6.21 | 6.16 | 8.86 | Upgrade
|
| Machinery | - | 14.52 | 11.99 | 11.57 | 8.87 | Upgrade
|
| Construction In Progress | - | - | - | 0.31 | 4.61 | Upgrade
|
| Leasehold Improvements | - | 15.42 | 17.65 | 9.3 | 5.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.